George Plain
Internal Medicine · Rochester, NYNPI 1881629145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,473 and has fallen 98.8% since, to $18 in 2024. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Pfizer$566
- Johnson & Johnson$328
- GSK$322
- Astellas Pharma US Inc$321
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,54698%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,020 |
| AbbVie(2 entities) | 68 | $1,018 |
| Pfizer | 43 | $566 |
| Johnson & Johnson | 18 | $328 |
| GSK | 18 | $322 |
| Astellas Pharma US Inc | 17 | $321 |
| Lilly USA, LLC | 19 | $292 |
| Amgen | 12 | $217 |
| Boehringer Ingelheim | 9 | $170 |
| AstraZeneca | 10 | $158 |
| Merck | 11 | $158 |
| Abbott | 7 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $131 |
| Novartis | 6 | $104 |
| Amarin Pharma, Inc. | 4 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Insulet Corporation | 3 | $72 |
| Bayer | 3 | $69 |
| Kowa Pharmaceuticals America, Inc. | 2 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Alkermes, Inc. | 3 | $55 |
| Ultragenyx Pharmaceutical Inc. | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Smith+Nephew | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Biogen | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,661 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 90 | $1,996 |
| Rosuvastatin Calcium | 72 | $1,731 |
| Levothyroxine Sodium | 77 | $1,562 |
| Valsartan | 50 | $1,372 |
| Amlodipine Besylate | 72 | $659 |
| Omeprazole | 37 | $625 |
| Lisinopril | 52 | $621 |
| Pantoprazole Sodium | 22 | $473 |
| Carvedilol | 28 | $444 |
| Tamsulosin Hcl | 23 | $424 |
| Metoprolol Succinate | 27 | $378 |
| Metformin Hcl ErMetformin Hcl | 23 | $288 |
| Gabapentin | 18 | $265 |
| Donepezil Hcl | 18 | $228 |
| Allopurinol | 15 | $208 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rochester
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.